Latest Pathoglaze News

Iperion reported a lower loss for the year ended 31 March 2026, but its cash reserves and net assets fell sharply, leaving the NZX-listed materials company reliant on related-party funding and director support. Its Pathoglaze manufacturing operation is also being moved from Malaysia to Singapore while customer trials continue.

Iperion Limited trimmed its net loss to $294,595 for the year to March 2026, aided by waived manufacturing fees and waived licence performance targets, while securing a $250,000 loan facility to underpin ongoing development of its antimicrobial Pathoglaze product.